Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Omarigliptin, A Weekly Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Management: Real-World Evaluation in Bangladesh

NCT06449235 is registered in ClinicalTrials.gov with Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders as lead sponsor.

NCT NCT06449235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06449235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Omarigliptin, A Weekly Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Management: Real-World Evaluation in Bangladesh
Lead sponsor
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Phase
Phase 4
Overall status
Unknown status
Start date
September 30, 2024
Completion date
June 30, 2025
Enrollment
938 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type2diabetes